BCM
ABCL icon

Blume Capital Management’s AbCellera Biologics ABCL Stock Holding History

Blume Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.2K Buy
4,484
+1,684
+60% +$8.23K 0.01% 227
2026
Q1 		$9.77K Hold
2,800
– – ﹤0.01% 273
2025
Q4 		$9.58K Buy
2,800
+700
+33% +$3.13K ﹤0.01% 264
2025
Q3 		$10.6K Buy
+2,100
New +$9.25K ﹤0.01% 273

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Blume Capital Management's ABCL Position: Q2 2026 in Review

Blume Capital Management increased its AbCellera Biologics (ABCL) stake by 60% in Q2 2026, buying an estimated $8.23K and bringing the position to 4,484 shares worth $35.2K. The position accounts for 0.01% of the portfolio, ranked #227.

Blume Capital Management first reported a position in ABCL in Q3 2025 and has held it in 4 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Blume Capital Management held 4,484 shares of AbCellera Biologics worth $35.2K as of Q2 2026.
  • Blume Capital Management bought 1,684 AbCellera Biologics shares in Q2 2026, an estimated $8.23K.
  • AbCellera Biologics made up 0.01% of Blume Capital Management's portfolio in Q2 2026, its #227 holding.
  • Blume Capital Management first reported a position in AbCellera Biologics in Q3 2025 and has held it in 4 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.